Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, Ali Zeaiter et al.|New England Journal of Medicine|2017Cited by 2.4k
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 293
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung‐Ju Ahn, Jaafar Bennouna, Kentaro Tanaka et al.|Journal of Clinical Oncology|2024Cited by 177
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Dae Ho Lee et al.|Journal of Clinical Oncology|2024Cited by 137
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancerAdam J. Schoenfeld, Matthew D. Hellmann, Scott Antonia et al.|Annals of Oncology|2021Cited by 98